跳至主要内容
临床试验/NL-OMON52484
NL-OMON52484招募中2 期

REStoring mood after Early life Trauma - Glucocorticoid Receptor (GR) blockade as disease-modifying treatment for depression with childhood trauma - RESET - medication

Vrije Universiteit Medisch Centrum0 个研究点目标入组 158 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
158

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • •Mastery of Dutch language
  • •Age of >= 18 years of age and able to give written IC
  • •Participant agrees to be randomized
  • •Moderate to severe depression
  • •Score >= 26 on the Inventory of Depressive Symptoms-Self Report (IDS-SR)
  • •DSM-5 diagnosis of major depression disorder (MDD), confirmed with clinical
  • •interview (MINI)
  • •Moderate to severe childhood trauma (CT) before the age of 18
  • •Score above validated cut-off for moderate to severe CT on one or more
  • •of the following
  • •domains using the Childhood Trauma Questionnaire (CTQ):
  • •* physical neglect: score >= 10
  • •* emotional neglect: score >= 15
  • •* sexual abuse: score >= 8
  • •* physical abuse: score >= 10
  • •* emotional abuse: score >= 13
  • •A female participant is eligible to participate if she is not pregnant or
  • •breastfeeding, and one of
  • •the following conditions applies:
  • •o Is not a WOCBP
  • •o Is a WOCBP and agrees to use an acceptable non-hormonal contraceptive
  • •(e.g. condom, also if hormonal contraceptive method is used) during the
  • •intervention period and up to 1 month after the intervention. A WOCBP must have
  • •a negative highly sensitive pregnancy test before the first dose of the study
  • •intervention.

排除标准

  • •A potential participant who meets any of the following criteria will be
  • •excluded from participation in this study:
  • •Primary diagnosis of post-traumatic stress disorder (PTSD) or Acute Stress
  • •Disorder (ASD)
  • •Lifetime diagnosis of borderline personality disorder (BPD)
  • •Current alcohol/drug dependence or other severe psychiatric comorbidity (e.g.
  • •bipolar disorder, schizophrenia) that requires clinical attention.
  • •Start of other forms of depression treatment in the week before or after
  • •randomization.
  • •Female participant being a WOCBP who do not agree to use an acceptable
  • •non-hormonal contraceptive method (e.g. condom, also if hormonal contraceptive
  • •method is used) during the intervention period and up to 1 month after the
  • •intervention.
  • •Female participants that are pregnant or breastfeeding. Pregnancy is excluded
  • •using a negative highly sensitive pregnancy test before the first dose of the
  • •study medication during the baseline visit.
  • •Female participants that have a history of unexplained vaginal bleeding or
  • •endometrial changes
  • •Chronic adrenal insufficiency
  • •Current use of:
  • •o Medications containing CYP3A4-inhibitors, as an interaction of
  • •CYP3A4-inhibitors and mifepristone leads to higher mifepristone plasma levels
  • •and increases the chance of having side effects. This also includes the
  • •consumption of grapefruit juice during the intervention
  • •o Medications containing CYP3A4-inductors, as an interaction of
  • •CYP3A4-inductors and mifepristone leads to lower mifepristone plasma levels and
  • •decreases the chance of having a beneficial effect. This also includes the
  • •consumption of St John*s worth /hypericum perforatum during the intervention.
  • •o Glucocorticoid antagonists within 1 week before possible start of trial
  • •o Systemic corticosteroids. Topical corticosteroid treatment are acceptable,
  • •with the exception of inhaled corticosteroids (inhalators).
  • •Before randomization, all currently used medications will be reviewed to
  • •prevent toxicity or interaction with mifepristone.

研究者

相似试验

REStoring mood after Early life Trauma -... | 临床试验